DOI: 10.7759/cureus.18900

Review began 10/16/2021 Review ended 10/17/2021 Published 10/19/2021

© Copyright 2021

Jha et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Bilateral Facial Palsy: A Case Study of an Exceedingly Rare and Difficult Diagnosis

Gaurav Jha ¹, Sabeen Azhar ², Shivani Kuttuva ³, Sameel Elahi ⁴, Asad Baseer ⁵

1. Neuroscience, Queen's Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust, London, GBR 2. Acute Medicine, Queen's Hospital, Barking, Havering and Redbridge University Hospitals NHS Trust, London, GBR 3. Surgery, Royal Vicoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, GBR 4. Acute Medicine, Princess Alexandra Hospital, The Princess Alexandra Hospital NHS Trust, Harlow, GBR 5. Orthopaedics, Leicester Royal infirmary, University Hospitals of Leicester NHS Trust, Leicester, GBR

Corresponding author: Gaurav Jha, gauravnancy.jha27@gmail.com

Abstract

Bilateral facial nerve palsy is a rare condition, representing only 0.3-2.0% of all facial palsy cases. Facial paralysis constitutes the result of a diverse array of systemic disorders and heterogeneous aetiologies and thus represents a diagnostic challenge. This case report describes a previously healthy male who presented to the emergency department numerous times within a few weeks with unrelated non-specific symptoms. These symptoms could not be attributed to any specific aetiology after various radiological and laboratory examinations, and hence presented a diagnostic dilemma until he developed bilateral seventh nerve palsy and was admitted for a further workup.

Categories: Neurology, Oncology, Pulmonology

Keywords: bell's palsy, bilateral facial palsy, heerfordt, sarcoidosis

Introduction

Unilateral facial palsy is a fairly common diagnosis with an incidence of 20-25 per 100,000 people. Most instances are linked to Bell's (i.e., idiopathic) palsy, accounting for more than 50% of these cases [1,2]. Bilateral facial paralysis, as opposed to unilateral facial paralysis, is exceedingly rare and accounts for only 0.3-2% of cases presenting with facial palsy [3]. The incidence of such cases is approximately one per five million per year [4]. Bilateral facial palsy is characterised by facial paralysis on both sides of the face, with the onset of symptoms on both sides either simultaneously or the second side being affected within 30 days of the first side [5]. Most of these patients have significant underlying medical problems and might exhibit bilateral facial paralysis as the first sign. Therefore, we recommend conducting a thorough investigation using both laboratory and radiological evidence to evaluate all instances of bilateral facial palsy.

Case Presentation

A 32-year-old Asian male presented to the emergency department with complaints of right-sided facial weakness, perioral numbness, speech difficulty, and altered taste sensation, which had started five days ago. Interestingly, he had been seen in the emergency department multiple times before this attendance and sent home with an outpatient neurology follow-up as the investigation results had been within the standard parameters. The patient also gave a history of a flu-like illness two weeks earlier. He had a past medical history of obstructive sleep apnea and bipolar disorder, and his regular medications included lithium carbonate and sodium valproate. He was a non-smoker and denied any alcohol or drug use.

The patient had been referred to be assessed by the stroke team. His symptoms had started with right-sided facial weakness, eventually progressing to the left side. He denied any history of trauma, rashes, travel abroad, or tick bites. On examination, he had a bilateral facial weakness with the inability to elevate eyebrows, puff out cheeks, or smile, and inadequate closure of the eyes (Figures 1-3). The neck was supple, and neurological examination revealed mild facial sensory deficits with bilateral lower motor neuron palsy. The rest of the neurological examination revealed no abnormalities. A complete blood count, comprehensive metabolic panel, and CT scan of the head did not reveal any significant findings. After a thorough exam, the stroke team ruled out a stroke, and the patient was handed over to the medical team for further workup.



FIGURE 1: Image showing inability to close both eyes



FIGURE 2: Image showing an attempt to raise eyebrows




FIGURE 3: Image showing an attempt to blow the cheeks

The neurology team advised a lumbar puncture to rule out infection before commencing any steroids. After two failed lumbar punctures in the lateral position due to increased basal metabolic index (BMI), a lumbar puncture was attempted in the sitting position, and cerebrospinal fluid (CSF) analysis showed the following results: glucose: 3.0, WBC: 6, lymphocytes: 6, RBC: <1, and protein: 0.75; Gram stain was negative. A CSF oligoclonal band was not detected. Electromyography (EMG) showed partial right facial nerve lesion, demyelinating in nature, and no signs of acute motor axonal loss and left facial lesions. Subsequent MRI head with contrast was unremarkable. No paraproteins were detected on serum electrophoresis, and the immunology, vasculitis, and viral screen were negative (Table 1).

Test	Value	Reference range	Units
	value	Reference range	Units
FBC			
Hb	125	130–180	g/L
WBC	10.5	4–11	10 ⁹ /L
RBC	4.58	4.5–6.5	10 ¹² /L
HCT	0.37	0.40–0.52	L/L
PLT	225	150–450	10 ⁹ /L
Neutrophils	8.3	2.0–7.5	10 ⁹ /L
Lymphocytes	1.7	1.5–4.5	10 ⁹ /L

Basophils 00 0-0.1 10°R ESR 20 1-10 mm/m PT 10.8 10.0-13.0 Seconds APTT 21.6 23-30 Seconds Serum B12 893 100-000 mpl Serum Iolidue 5.5 3-20.0 mpl Biochemistry W W W Biochemistry W 133-146 mmolt Potassium 5.0 3.5-5.3 mmolt Urea 3.7 mmolt 12-7.8 mmolt ALP 64 10-5 10-1 mmolt ALT 5.2 10-1 10-1 10-1 ALT 5.2 22-2.6 mmolt 10-1 10-1 10-1 ACIGUM 1.2 3.2 22-2.6 mmolt 10-1 10-1 10-1 10-1 10-1 10-1 10-1 10-1 10-1 10-1 10-1 10-1 10-1 10-1 10-1 10-1	Monocytes	0.5	0.2–0.8	10 ⁹ /L
ESR 20 1-10 mm/hr PT 10.8 10.0-13.0 Seconds APTT 21.6 3-30 Seconds Serum B12 983 180-900 ng1 Serum Glate 5.9 2-20.0 µg/L Fermin 255 20-300 µg/L Blochmistry 5.0 33-146 mmol/L Polassium 5.0 35-5.3 mmol/L Urea 3.7 59-104 mmol/L Creatinine 70 59-104 mmol/L ALP 64 30-130 U/L ALP 64 30-130 U/L ALP 1.25 mmol/L 10-50 U/L ALT 56 1.25 mmol/L 10-10 mmol/L Phosphate 1.25 0.8-1.5 mmol/L 10-10 Mmol/L GGT 2.2 2.6 mmol/L 10-10 mmol/L Triglycerides 1.36 1.0 1.0	Eosinophils	0.0	0-0.4	10 ⁹ /L
PT 10.8 10.0-13.0 Seconds APTT 21.6 23-30 Seconds Senum B12 983 180-900 ng/I Serum Iodate 5.9 3-20.0 ug/L Forritin 255 20-300 ug/L Biochemistry WI Second 180 20-300 ug/L Biochemistry Solidium 142 33-146 mmol/L Urea 3.7 3-5-7.8 mmol/L Creatisine 70 59-104 mmol/L ALP 64 30-130 U/L ALP 64 10-50 U/L ALP 64 10-50 U/L Celoitum 2.32 22-2.6 mmol/L Phosphate 1.25 0.8-1.5 mmol/L GGT 2.2 2.6 mmol/L Cholestored 4.8 0.5 mmol/L HOLocholestored 4.8 0.5 mmol/L GUlcose 8.9 5.5	Basophils	0.0	0–0.1	10 ⁹ /L
APTT 21-6 23-30 Second Serum B12 983 190-900 ng/l Serum folate 5.9 3-20.0 ug/l Fermitn 25-5 20-300 ug/l Blochemistry W W 133-146 mmol/L Potassium 5.0 3.5-5.3 mmol/L Potassium 5.0 3.7 mmol/L 25-7-8 mmol/L Creatinine 70 59-104 mmol/L mmol/L 4 ALP 46 30-130 U/L 4 1 </td <td>ESR</td> <td>20</td> <td>1–10</td> <td>mm/hr</td>	ESR	20	1–10	mm/hr
Samum B12 983 180-900 ng/l Serum folate 5.9 3-20.0 µg/L Ferritin 255 20-300 µg/L Blochemistry W 142 133-146 mmol/L Potassium 5.0 3.5-8.3 mmol/L Urea 3.7 2.5-7.8 mmol/L Ceatinine 70 59-104 mmol/L ALP 64 30-130 U/L ALT 56 10-50 U/L Calcium 2.32 22-2.6 mmol/L Phosphate 1.25 0.8-1.5 mmol/L GGT 2 0-60 U/L Amylase 121 28-100 U/L Cholesterol 4.8 0-5.0 mmol/L Triglycerides 1.36 1-2.3 mmol/L HDL cholesterol 4.8 1.0-3.0 mmol/L CRP 11 4.8 1.0-3.0 mmol/L CRP 14 4.8 1	PT	10.8	10.0–13.0	Seconds
Serum folate 5.9 3-20.0 µg/L Ferritin 255 20-300 µg/L Biochemistry Sodium 142 133-146 mmol/L Potassium 5.0 3.5-6.3 mmol/L Urea 3.7 2.5-7.8 mmol/L ALP 64 30-130 U/L ALT 56 10-60 U/L Calcium 2.32 22-2.6 mmol/L Phosphate 1.25 0.8-1.5 mmol/L GGT 22 0-60 U/L Amylase 121 28-100 U/L Cholesterol 4.8 0-5.0 mmol/L Triglycerides 1.36 1-2-3.0 mmol/L LDL cholesterol 4.8 1.0-3.0 mmol/L LDL cholesterol 4.8 1.0-3.0 mmol/L CRP 11 4.5 mg/L ACE 4.8 1.0-3.0 mmol/L CRF analysis 5 mg/L	APTT	21.6	23–30	Seconds
Ferritin 255 20-300 µg/L Biochemistry Sodium 142 133-146 mmol/L Potassium 5.0 3.5-5.3 mmol/L Lirea 3.7 2.5-7.8 mmol/L Creatinine 70 99-104 mmol/L ALP 64 30-130 U/L ALT 56 10-50 U/L Calcium 2.32 2.2-2.6 mmol/L Phosphate 1.25 0.8-1.5 mmol/L GGT 2.2 0.60 U/L Amylase 121 2.0 0.60 U/L Cholesterol 4.8 0.5.0 mmol/L Triglycerides 1.36 1.0 1.0 mmol/L LDL cholesterol 4.8 1.0-3.0 mmol/L LDL cholesterol 4.8 1.0-3.0 mmol/L CRP 11 4.5 mmol/L CSF plicose 3.0 5.5 mmol/L CSF prictein <td>Serum B12</td> <td>983</td> <td>180–900</td> <td>ng/l</td>	Serum B12	983	180–900	ng/l
Biochemistry Sodium 142 monoil. Potassium 5.0 3.5-3.3 mmolit. Lirea 3.7 59-104 mmolit. Creatinine 70 59-104 mmolit. ALP 64 30-130 U/L ALT 56 10-50 U/L Calcium 3.32 22-2.6 mmolit. Phosphate 1.25 0-60 U/L Amylase 121 28-100 U/L Cholesterol 4.8 0-5.0 mmolit. Triglycerides 1.36 mmolit. mmolit. HDL cholesterol 4.8 0-1.7 mmolit. LDL cholesterol 4.8 1.0-3.0 mmolit. LDL cholesterol 4.8 1.0-3.0 mmolit. CRP 11 5 mmolit. ACE 48.4 5 mmolit. CSF pilicose 3.0 5-80 mmolit. CSF pilicose 3.0	Serum folate	5.9	3–20.0	μg/L
Sodium 142 133-146 mmol/L Potassium 5.0 3.5-5.3 mmol/L Urea 3.7 2.5-7.8 mmol/L Creatinine 70 59-104 mmol/L ALP 64 30-130 U/L ALT 56 10-50 U/L Calcium 2.32 22-2.6 mmol/L Phosphate 1.25 mmol/L mmol/L GGT 22 0-60 U/L Amylase 121 28-100 U/L Cholesterol 4.8 0-5.0 mmol/L HDL cholesterol 0.82 1.2-3.0 mmol/L LDL cholesterol 4.8 1.0-3.0 mmol/L Glucose 8.9 45.5 mmol/L CRP 11 45 mg/L ACE 48.4 52 U/L CSF analysis CSF glucose 3.0 50-80 mg/I CSF protein 0.30 1.5-0.45 mm³	Ferritin	255	20–300	μg/L
Potassium 5.0 3.5-6.3 mmol/L Urea 3.7 2.5-7.8 mmol/L Creatinine 70 59-104 mmol/L ALP 64 30-130 U/L ALT 56 10-50 U/L Calcium 2.32 22-2.6 mmol/L Phosphate 1.25 mmol/L mmol/L GGT 2.2 0-60 U/L Amylase 121 28-100 U/L Cholosterol 4.8 0-5.0 mmol/L Triglycerides 1.36 0-1.7 mmol/L HDL cholesterol 0.82 1.2-3.0 mmol/L LDL cholesterol 4.8 1.0-3.0 mmol/L Glucose 8.9 <5.5	Biochemistry			
Urea 3.7 mmol/L Creatinine 70 59-104 mmol/L ALP 64 30-130 U/L ALT 56 10-50 U/L Calcium 2.32 2.2-2.6 mmol/L Phosphate 1.25 0.8-1.5 mmol/L GGT 2 0-60 U/L Amylase 121 28-100 U/L Cholesterol 4.8 0-5.0 mmol/L Cholesterol 4.8 0-1.7 mmol/L HDL cholesterol 8.82 1.2-3.0 mmol/L LDL cholesterol 4.8 1.0-3.0 mmol/L CRP 11 <5	Sodium	142	133–146	mmol/L
Creatinine 70 59-104 mmol/L ALP 64 30-130 U/L ALT 56 10-50 U/L Calcilum 2.32 2.2-2.6 mmol/L Phosphate 1.25 0.8-1.5 mmol/L GGT 2 0-60 U/L Amylase 121 28-100 U/L Cholesterol 4.8 0-5.0 mmol/L Triglycerides 1.36 0-1.7 mmol/L HDL cholesterol 0.82 1.2-3.0 mmol/L LDL cholesterol 4.8 1.0-3.0 mmol/L GRP 11 4.5 mmol/L CRP 11 4.5 mmol/L CSF glucose 3.0 5.5 mmol/L CSF glucose 3.0 50-80 mg/I tomL CSF protein 0.30 0.15-0.45 g/L CSF viral PCR screen Not detected Mmol/L mmol/L WBCs 6 0.8 mmol/L	Potassium	5.0	3.5–5.3	mmol/L
ALP 64 64 30–130 U/L ALT 56 10–50 U/L Calcium 2.32 22–2.6 mmol/L Phosphate 1.25 0.8–1.5 mmol/L GGT 22 0.60 U/L Amylase 121 28–100 U/L Cholesterol 4.8 0.5.0 mmol/L Triglycerides 1.36 0.1.7 mmol/L HDL cholesterol 0.82 1.2–3.0 mmol/L LDL cholesterol 4.8 1.0–3.0 mmol/L LDL cholesterol 4.8 1.0–3.0 mmol/L CRP 11 0.80 4.8 1.0–3.0 mmol/L CRP 11 0.80 4.8 1.0–3.0 mmol/L CSF analysis CSF analysis CSF analysis CSF spilocose 3.0 50–80 mg/100mL CSF protein 0.30 50–80 mg/100mL CSF protein 0.30 50–80 mg/100mL CSF protein 0.50 0.60 0.80 mg/100mL CSF viral PCR screen Not detected WBCs 6 0.80 0.80 0.80 0.80 mg/3 RBCs 1 0.90 0.90 mm/3 RBCs 1 0.90 0.90 mm/3 RBCs 1 0.90 0.90 mm/3 Culture No growth after 48h incubation Ach. Receptor abs 0.34 0.90 mmol/L	Urea	3.7	2.5–7.8	mmol/L
ALT 56 10-50 U/L Calcium 2.32 2.2-2.6 mmol/L Phosphate 1.25 0.8-1.5 mmol/L GGT 22 0-60 U/L Amylase 121 28-100 U/L Cholesterol 4.8 0-5.0 mmol/L Triglycerides 1.36 0-1.7 mmol/L HDL cholesterol 0.82 1.2-3.0 mmol/L LDL cholesterol 4.8 1.0-3.0 mmol/L Glucose 8.9 5.5 mmol/L CRP 11 <5	Creatinine	70	59–104	mmol/L
Calcium 2.32 2.2-2.6 mmol/L Phosphate 1.25 0.8-1.5 mmol/L GGT 22 0-60 U/L Amylase 121 28-100 U/L Cholesterol 4.8 0-5.0 mmol/L Triglycerides 1.36 0-1.7 mmol/L HDL cholesterol 0.82 1.2-3.0 mmol/L Glucose 8.9 <5.5	ALP	64	30–130	U/L
Phosphate 1.25 mmol/L GGT 22 0-60 U/L Amylase 121 28-100 U/L Cholesterol 4.8 0-5.0 mmol/L Triglycerides 1.36 0-1.7 mmol/L HDL cholesterol 0.82 1.2-3.0 mmol/L LDL cholesterol 4.8 1.0-3.0 mmol/L Glucose 8.9 5.5 mmol/L CRP 11 5 mg/L ACE 48.4 5-2 I/L CSF analysis U/L 50-80 mg/10omL CSF glucose 3.0 50-80 mg/10omL CSF protein 0.30 0.15-0.45 g/L CSF viral PCR screen Not detected mm³ RBCs 4 -8 -8 mm³ RBCs 4 -8 -8 mm³ Gram stain No organism seen -8 mm³/L mm³/L Culture No growth after 48h incubation <t< td=""><td>ALT</td><td>56</td><td>10–50</td><td>U/L</td></t<>	ALT	56	10–50	U/L
GGT 22 0-60 U/L Amylase 121 28-100 U/L Cholesterol 4.8 0-5.0 mmol/L Triglycerides 1.36 0-1.7 mmol/L HDL cholesterol 0.82 1.2-3.0 mmol/L LDL cholesterol 4.8 1.0-3.0 mmol/L Glucose 8.9 <5.5	Calcium	2.32	2.2–2.6	mmol/L
Amylase 121 28-100 U/L Cholesterol 4.8 0-5.0 mmol/L Triglycerides 1.36 0-1.7 mmol/L HDL cholesterol 0.82 1.2-3.0 mmol/L LDL cholesterol 4.8 1.0-3.0 mmol/L Glucose 8.9 <5.5	Phosphate	1.25	0.8–1.5	mmol/L
Cholesterol 4.8 0-5.0 mmol/L Triglycerides 1.36 0-1.7 mmol/L HDL cholesterol 0.82 1.2-3.0 mmol/L LDL cholesterol 4.8 1.0-3.0 mmol/L Glucose 8.9 <5.5	GGT	22	0–60	U/L
Triglycerides 1.36 0-1.7 mmol/L HDL cholesterol 0.82 1.2-3.0 mmol/L LDL cholesterol 4.8 1.0-3.0 mmol/L Glucose 8.9 <5.5	Amylase	121	28–100	U/L
HDL cholesterol 0.82 1.2-3.0 mmol/L LDL cholesterol 4.8 1.0-3.0 mmol/L Glucose 8.9 <5.5	Cholesterol	4.8	0–5.0	mmol/L
LDL cholesterol 4.8 1.0-3.0 mmol/L Glucose 8.9 <5.5	Triglycerides	1.36	0–1.7	mmol/L
Glucose 8.9 <5.5 mmol/L CRP 11 <5	HDL cholesterol	0.82	1.2–3.0	mmol/L
CRP 11 5 mg/L ACE 48.4 8–52 IU/L CSF analysis USF glucose 3.0 50–80 mg/100mL CSF protein 0.30 0.15–0.45 g/L CSF oligoclonal band Negative - - CSF viral PCR screen Not detected -8 mm³ RBCs 6 0–8 mm³ RBCs 1 mm³ Gram stain No organism seen - - Culture No growth after 48h incubation - - Ach. Receptor abs 0.34 -	LDL cholesterol	4.8	1.0–3.0	mmol/L
ACE 48.4 8–52 IU/L CSF analysis CSF glucose 3.0 50–80 mg/100mL CSF protein 0.30 0.15–0.45 g/L CSF oligoclonal band Negative - - CSF viral PCR screen Not detected - mm³ RBCs 1 - mm³ Gram stain No organism seen - mm³ Culture No growth after 48h incubation - nmol/L Serology - - - -	Glucose	8.9	<5.5	mmol/L
CSF analysis CSF glucose 3.0 50–80 mg/100mL CSF protein 0.30 0.15–0.45 g/L CSF oligoclonal band Negative	CRP	11	<5	mg/L
CSF glucose 3.0 50–80 mg/100mL CSF protein 0.30 0.15–0.45 g/L CSF oligoclonal band Negative	ACE	48.4	8–52	IU/L
CSF protein 0.30 0.15–0.45 g/L CSF oligoclonal band Negative	CSF analysis			
CSF oligoclonal band Negative CSF viral PCR screen Not detected WBCs 6 0-8 mm³ RBCs <1 <1 mm³ Gram stain No organism seen Culture No growth after 48h incubation Ach. Receptor abs 0.34 <0.5 nmol/L Serology	CSF glucose	3.0	50–80	mg/100mL
CSF viral PCR screen Not detected WBCs 6 0–8 mm³ RBCs <1 <1 mm³ Gram stain No organism seen	CSF protein		0.15–0.45	g/L
WBCs 6 mm³ RBCs <1	CSF oligoclonal band	Negative		
RBCs <1 <1 mm³ Gram stain No organism seen	CSF viral PCR screen	Not detected		
Gram stain No organism seen Culture No growth after 48h incubation Ach. Receptor abs 0.34 <0.5 nmol/L Serology	WBCs	6	0–8	mm^3
Culture No growth after 48h incubation Ach. Receptor abs 0.34 < 0.5 nmol/L Serology	RBCs	<1	<1	mm^3
Ach. Receptor abs 0.34 <0.5 nmol/L Serology	Gram stain	No organism seen		
Serology	Culture	No growth after 48h incubation		
	Ach. Receptor abs	0.34	<0.5	nmol/L
HIV 1,2 Ab p24 Ag Not detected	Serology			
	HIV 1,2 Ab p24 Ag	Not detected		

HSV 1 DNA PCR	DNA not detected	
HSV 2 DNA PCR	DNA not detected	
VZV DNA (qualitative)	DNA not detected	
HBsAg (EIA)	Not detected	
EBV screen	Not detected	
Enterovirus RNA PCR	RNA not detected	
Treponemal Ab	Not detected	
B. burgdorferi IgG/IgM	Negative, no serological evidence of B. burgdorferi	

TABLE 1: Laboratory test results

FBC: full blood count; Hb: hemoglobin; WBC: white blood cell; RBC: red blood cell; HCT: hematocrit; PLT: platelets; ESR: erythrocyte sedimentation rate; PT: prothrombin time; APTT: activated partial thromboplastin time; ALP: alkaline phosphatase; ALT: alanine aminotransferase; GGT: gamma-glutamyl transferase; HDL: high-density lipoproteins; LDL: low-density lipoprotein; CRP: C-reactive protein; ACE: angiotensin-converting enzyme; CSF: cerebrospinal fluid; Ach: acetylcholine; HIV: human immunodeficiency virus; HSV: herpes simplex virus; VZV: varicella-zoster virus; DNA: deoxyribonucleic acid; RNA: ribonucleic acid; HBsAg: hepatitis B surface antigen; EIA: enzyme immunoassay; EBV: Epstein-Barr virus, PCR: polymerase chain reaction; Ab: antibody; IgG: immunoglobulin G; IgM: immunoglobulin M

More information came to light during a thorough and detailed history taking. Family history revealed that both the patient's mother and sister had bilateral facial palsy, and his mother had been diagnosed with sarcoidosis. At this point, serum angiotensin-converting enzyme (ACE) level was requested due to the suspicion of sarcoidosis and was found to be within the range. Chest radiograph showed no hilar adenopathy. A CSF ACE level was not requested, and hence sarcoidosis could not be completely ruled out. An eye examination conducted to check for ocular manifestations revealed no abnormalities.

On day six of admission, the patient was commenced on oral steroids after a central nervous system (CNS) infection was ruled out. By this time, there had been a complete resolution of the left-sided facial weakness and the initial complaint of the neck pain; however, the right-sided facial palsy and the pain around the ears were still present. Otolaryngological examination revealed tenderness in the parotids and submandibular region even though the glands were not enlarged. Hence, a clinical diagnosis of Heerfordt syndrome was considered. The patient was advised to complete a 10-day course of steroids and sent home with eye patches once his symptoms were found to be improving.

Follow-up at one week showed improvement in right-sided facial weakness as well. Slurring of speech became better but did not revert to baseline. The patient has developed no additional symptoms and is currently under outpatient neurology follow-up.

Discussion

A significant difficulty for clinicians in numerous specialities and care settings is determining the appropriate triage of patients with acute facial paralysis. Bilateral facial palsy is often a manifestation of a severe underlying systemic disease and warrants urgent medical intervention, unlike unilateral presentation, which is usually secondary to idiopathic Bell's palsy and is often not investigated further. A recent review identified a misdiagnosis rate of <1% in the emergency setting, but previous literature has suggested rates as high as 20%, with 5% of lower motor facial paralysis being attributed to tumours [6]. The aetiologies of bilateral facial palsy can include congenital, infectious, vascular, metabolic, autoimmune, neoplastic, neurological, or traumatic causes [7,8]. It is crucial to identify the underlying cause because treatment and prognosis depend on it. After the initial blood-work, additional investigations should be guided by a detailed history and physical examination.

Symptom characterisation (e.g., time of onset), associated symptoms (diplopia, facial numbness, otological symptoms, aphasia), relevant risk factors (e.g., viral prodrome, immunisation), and prior palsy history can give us clues towards the diagnosis. In our case of bilateral facial nerve palsy, the patient did provide an account of flu-like illness two weeks before this presentation. However, no consideration was given to antiviral treatment, which is a retrospective thing because antivirals can be considered in cases with a strong history of viral prodrome. The American Academy of Neurology (AAN) and American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) have recommended administration of oral steroids (prednisone 50-60 mg daily) and, less strongly, antiviral medications (acyclovir or valacyclovir) to patients with new (defined as <72 hours in onset by AAO-HNSF) Bell's palsy [9].

A reasonable approach is to start by ruling out potentially life-threatening causes like Guillain-Barré syndrome (GBS) by looking for peripheral areflexia and liquoric dissociation on a CSF analysis as GBS

presenting with facial nerve palsy is fatal in up to 50% of the cases [10]. It is equally important to rule out intrapontine and prepontine tumours along with traumatic fractures by doing a CT or preferably an MRI of the brain [11]. In our case of bilateral facial nerve palsy, CSF analysis was within normal parameters, and brain imaging revealed no abnormalities.

Bilateral facial nerve palsy that develops rapidly, like in our case over a few days, suggested more of an infectious or autoimmune aetiology, especially in a setting with no history of trauma. Moreover, synchronous palsy with the involvement of the contralateral side within 30 days also pointed towards a systemic disease rather than a localised inflammatory condition [12].

Lyme disease is the most common among other infectious causes of bilateral facial nerve palsy (30%-35%) and was ruled out by negative serology [13]. It was also deemed unlikely as our patient denied any recent travel to endemic areas or contact with ticks. An acute Epstein-Barr virus (EBV) infection was excluded by a negative Epstein-Barr virus capsid antigen (VCA) IgM antibody test. Other common systemic causes include diabetes, which was ruled out by normal blood sugar levels.

Interestingly, although the history of symptom onset was suggestive of autoimmune aetiologies like sarcoidosis and amyloidosis, no initial workup was done to explore these causes. Sarcoidosis was not deemed a possible cause until it was discovered that the patient's mother had sarcoidosis and complained of bilateral parotid pain. At this point, serum ACE levels were requested, and a chest X-ray was ordered to exclude hilar adenopathy. Sarcoidosis is a multi-system granulomatous disorder of unknown aetiology, which most commonly affects the pulmonary system. Neurological manifestations include cranial neuropathies, the most frequently affected being the facial nerve (unilateral palsy in 1-3% and bilateral palsy in 0.1-0.2% of cases) [14]. Diagnosis is supported by serum ACE levels, tissue biopsy of affected organs, and enlarged lymph nodes on a chest CT. With no apparent systemic involvement, a biopsy was not indicated. However, it is worth considering whether a CT chest should have been requested as an initial workup.

Glucocorticoids for two weeks are indicated in the treatment of bilateral facial nerve palsy if sarcoidosis is the suspected or confirmed cause. Even though steroid treatment was initiated in our case, it is worth noting that it was commenced on day six of admission when the left-sided weakness had started to improve. Eventually, the right-sided weakness improved as well but did not resolve completely. Although there is no established association between the time of initiation of steroids and prognosis, this case nevertheless highlights the importance of early consideration by the physician for the use of empiric corticosteroids given their efficacy in numerous differential diagnoses. Early neurology consultation in these cases ensures such decisions are not delayed.

Thus, in our case, although our patient was eventually discharged with the clinical diagnosis of Heerfordt syndrome, it was a diagnostic dilemma as investigations could not confirm it. Heerfordt syndrome is an acute and rare presentation of sarcoidosis. It manifests as fever, uveitis, and bilateral parotid swelling with bilateral facial palsy. However, the typical presentation of this syndrome is rare and is seen in 0.3-1.2% of cases of sarcoidosis [15]. Very rarely, bilateral facial nerve palsy can present as an initial isolated manifestation of sarcoidosis. It would be interesting to follow these patients to see if they develop sarcoidosis later on in life.

Conclusions

Bilateral facial nerve palsy is an uncommon and diagnostically challenging presentation. Our case report highlights the importance and need for a thorough history taking, including family history, physical examination, and investigating the full spectrum of possible diagnoses in all instances presenting with bilateral facial nerve palsy instead of going in with a tunnel vision. Bilateral facial paralysis has a variety of causes, and the manifestation of Heerfordt syndrome is variable. Hence, a complete understanding of this condition can assist the clinician in making a proper and accurate diagnosis. While management varies by aetiology, the physician should consider early empiric corticosteroids given their efficacy in numerous differential diagnoses.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. George MK, Pahor AL: Sarcoidosis: a cause for bilateral facial palsy . Ear Nose Throat J. 1991, 70:492-3.

- Price T, Fife DG: Bilateral simultaneous facial nerve palsy. J Laryngol Otol. 2002, 116:46-8.
 10.1258/0022215021910113
- Stahl N, Ferit T: Recurrent bilateral peripheral facial palsy . J Laryngol Otol. 1989, 103:117-9. 10.1017/s0022215100108199
- Teller DC, Murphy TP: Bilateral facial paralysis: a case presentation and literature review . J Otolaryngol. 1992. 21:44-7.
- 5. May M, Klein SR: Differential diagnosis of facial nerve palsy . Otolaryngol Clin North Am. 1991, 24:613-45.
- 6. Fahimi J, Navi BB, Kamel H: Potential misdiagnoses of Bell's palsy in the emergency department . Ann Emerg Med. 2014, 63:428-34. 10.1016/j.annemergmed.2013.06.022
- 7. Steenerson RL: Bilateral facial paralysis. Am J Otol. 1986, 7:99-103.
- 8. Yang A, Dalal V: Bilateral facial palsy: a clinical approach. Cureus. 2021, 13:e14671. 10.7759/cureus.14671
- Gronseth GS, Paduga R: Evidence-based guideline update: steroids and antivirals for Bell palsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2012, 79:2209-13. 10.1212/WNL.0b013e318275978c
- Arias G, Nogués J, Mañós M, Amilibia E, Dicenta M: Bilateral facial nerve palsy: four case reports. ORL J Otorhinolaryngol Relat Spec. 1998, 60:227-9. 10.1159/000027599
- 11. Keane JR: Bilateral seventh nerve palsy: analysis of 43 cases and review of the literature . Neurology. 1994, 44:1198-202. 10.1212/wnl.44.7.1198
- 12. Gaudin RA, Jowett N, Banks CA, Knox CJ, Hadlock TA: Bilateral facial paralysis: a 13-year experience . Plast Reconstr Surg. 2016, 138:879-87. 10.1097/PRS.0000000000002599
- Pothiawala S, Lateef F: Bilateral facial nerve palsy: a diagnostic dilemma . Case Rep Emerg Med. 2012, 2012:458371. 10.1155/2012/458371
- 14. Ozkara B, Budak F: Bilateral facial paralysis. Eurasian J Med Invest. 2018, 2:41-4. 10.14744/ejmi.2017.97752
- Chappity P, Kumar R, Sahoo AK: Heerfordt's syndrome presenting with recurrent facial nerve palsy: case report and 10-year literature review. Sultan Qaboos Univ Med J. 2015, 15:e124-8.